Access to Birth Control for All

Summary#

The Access to Birth Control Act would amend the Public Health Service Act; it is not yet law. It would set duties for certain pharmacies to provide contraception and related medication, with the stated goal of ensuring provision without delay.

• A pharmacy that receives FDA-approved, cleared, or authorized drugs or devices through interstate commerce would have to provide a requested contraceptive or related medication that is in stock without delay.
• If the item is not in stock, a pharmacy that ordinarily stocks contraception or related medication would have to tell the customer immediately and offer a referral or prescription transfer, or expedited ordering.
• Pharmacies would have to prevent intimidation, obstruction, certain misleading statements, breaches or threats to breach confidentiality, and refusal to return a valid prescription when asked.
• The bill would allow certain refusals: when a required valid prescription is missing, the customer cannot pay, or an employee makes a refusal based on professional clinical judgment.
• Violations could lead to a federal civil penalty and a lawsuit by an aggrieved person. The bill would take effect 31 days after enactment, even if federal guidance or rules have not been issued.

What it means for you#

• Customers: At a covered pharmacy, an in-stock item would have to be provided without delay, subject to the bill’s exceptions. If the pharmacy ordinarily stocks these products but is out, it must offer the listed referral, transfer, or expedited-order options.
• Customers: The bill does not require a pharmacy to stock contraception if it does not ordinarily stock it. It also does not require free products, and inability to pay is an allowed reason to refuse provision.
• Pharmacies and their employees: They would have to follow the provision, referral or ordering, and conduct requirements. The term “pharmacy” covers an entity authorized by a state to sell prescription drugs at retail that employs at least one person.
• Taxpayers: The bill creates a federal civil penalty, but the text does not identify which agency would handle penalty cases.

Money#

No cost information is in the available material.

• The bill authorizes a federal civil penalty of up to $1,000 per day of violation, capped at $100,000 for all violations adjudicated in one proceeding.
• An aggrieved person could sue for appropriate relief, including actual and punitive damages, an injunction, and reasonable attorney fees and costs.
• The bill does not estimate pharmacy costs, federal enforcement costs, or any public savings.

What is unclear#

• “Medication related to contraception” includes a drug or device a medical professional determines is necessary before or in conjunction with contraception. The bill does not explain who makes that determination in a dispute.
• “Without delay” means within the pharmacy’s usual and customary timeframe for similar products. The bill does not set a fixed number of hours or days.
• The text does not name the federal agency or process for handling civil penalties, or explain how alleged violations would be investigated.
• The bill refers to a “covered title” in its rule about the Religious Freedom Restoration Act, but the supplied text does not define that term.
• The bill does not explain how its requirements interact with other federal rules beyond preserving rights and remedies under Title VII and not displacing stronger state protections.
• It was introduced in the Senate and is not law. Its passage is uncertain; the bill text does not provide funding or require guidance before its duties take effect.

Case for#

• The bill appears intended to address delays or refusals in obtaining contraception at pharmacies.
• Requiring an in-stock product to be provided, while giving customers a choice of referral, transfer, or ordering when it is out of stock, could offer a clear path to obtain it.
• The conduct rules could protect customers’ privacy and reduce obstruction, intimidation, or misleading information.
• The exceptions preserve refusal when a prescription is legally required but missing, when the customer cannot pay, or when a refusal rests on professional clinical judgment.

Case against#

• One concern is that the bill sets duties and allows lawsuits but does not spell out a federal process for resolving complaints or deciding penalties.
• The “related medication” definition and the clinical-judgment exception may be difficult to apply consistently; the bill does not give further standards for disputes.
• The bill’s timing standard depends on each pharmacy’s usual practice, rather than a specific deadline.
• A possible trade-off is that pharmacies could face penalties or litigation, including claims for punitive damages, while the bill does not estimate compliance or enforcement costs.